Dianthus Therapeutics, Inc. /DE/ (DNTH): auditor change — Dianthus Therapeutics appoints Deloitte & Touche as new independent auditor

Dianthus Therapeutics, Inc. /DE/

Deloitte & Touche LLP appointed as independent registered public accounting firm effective October 19, 2023.
No disagreements, reportable events, or prior consultations with Deloitte regarding accounting principles.
Appointment follows completion of merger with Dianthus Therapeutics OpCo, Inc. in September 2023.

item 4.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.95

Dianthus Therapeutics, Inc. /DE/ engaged Deloitte & Touche LLP as its auditor.

Action: engagement
Auditor: Deloitte & Touche LLP

Exact text from the filing

on September 11, 2023, following the completion of the merger between the subsidiary of Dianthus Therapeutics, Inc. (the "Company," formerly known as Magenta Therapeutics, Inc.) and Dianthus Therapeutics OpCo, Inc. (formerly known as Dianthus Therapeutics, Inc.), the Audit Committee of the Company approved the appointment of Deloitte & Touche LLP (“Deloitte”) as the independent registered public accounting firm of the Company. The Company’s engagement of Deloitte was subject to completion of Deloitte’s standard client acceptance procedures and execution of an engagement letter, which was fully executed by the Company on October 19, 2023

View on SEC.gov

17 auditor changes filed in the last 30 days. Browse all auditor changes →

Dianthus Therapeutics, Inc. /DE/ filing history →

Source: SEC EDGAR

accession 0000950170-23-055193

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.